Filing Flows › Janux Therapeutics (JANX) › Recalls, complaints & regulation

Janux Therapeutics (JANX): clinical trials

Janux Therapeutics (JANX) beyond its filings: 5 active clinical trials.

Janux Therapeutics' latest quarter

Janux Therapeutics, Q3 2026: revenue $9.3M (-7% year over year), operating margin -336.5%, net loss $21.6M, operating cash flow −$25.2M. The chart follows the revenue to costs, profit and cash.

Questions

How many clinical trials does Janux Therapeutics have?

5 active studies on ClinicalTrials.gov, 0 in phase 3.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.